ClinicalTrials.gg

Program

LTZ-232

A development code.

Its studies are mostly in Colonic Neoplasms, led by LTZ Therapeutics.

Furthest: phase 1, since Oct 11, 20261 company-led study, 1 open or runningNext primary completion: Dec 2031 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LTZ Therapeutics11 open or runningphase 1since Oct 11, 2026Oct 11, 2026Dec 2031phase 1 · NCT07878988

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 11, 2026First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT07878988 · 152 planned · United States

Ahead

  1. Dec 2031Primary completion: phase 1 study in Colorectal NeoplasmsNCT07878988

TargetBeta

EPCAM →read by rule
“LTZ-232 is an engineered anti-EPCAM bispecific antibody designed to activate tumor-associated macrophages to phagocytose and kill tumor cells.”study text, by rule · the study

Other programs on EPCAM

ProgramCompanyFurthest phaseStudies
adecatumumabrulemirador-therapeutics-incphase 24
Anti-EpCAM/Anti-4-1BB Bispecific Antibody BNT314ruleBioNTechphase 22

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07878988Colorectal Neoplasms · United States1RecruitingDec 2031152

How it is read

Names in the registry

  • “LTZ-232”, 1 entry

Codes read as this program: LTZ232.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.